Literature DB >> 16010676

Beckwith-Wiedemann syndrome.

Rosanna Weksberg1, Cheryl Shuman, Adam C Smith.   

Abstract

Beckwith-Wiedemann syndrome (BWS) is a clinically heterogeneous overgrowth syndrome associated with an increased risk for embryonal tumor development. BWS provides an ideal model system to study epigenetic mechanisms. This condition is caused by a variety of genetic or epigenetic alterations within two domains of imprinted growth regulatory genes on human chromosome 11p15. Molecular studies of BWS have provided important data with respect to epigenotype/genotype-phenotype correlations; for example, alterations of Domain 1 are associated with the highest risk for tumor development, specifically Wilms' tumor. Further, the elucidation of the molecular basis for monozygotic twinning in BWS defined a critical period for imprint maintenance during pre-implantation embryonic development. In the future, such molecular studies in BWS will permit enhanced medical management and targeted genetic counseling. Copyright 2005 Wiley-Liss, Inc.

Entities:  

Mesh:

Year:  2005        PMID: 16010676     DOI: 10.1002/ajmg.c.30058

Source DB:  PubMed          Journal:  Am J Med Genet C Semin Med Genet        ISSN: 1552-4868            Impact factor:   3.908


  76 in total

1.  Maternal gametic transmission of translocations or inversions of human chromosome 11p15.5 results in regional DNA hypermethylation and downregulation of CDKN1C expression.

Authors:  Adam C Smith; Masako Suzuki; Reid Thompson; Sanaa Choufani; Michael J Higgins; Idy W Chiu; Jeremy A Squire; John M Greally; Rosanna Weksberg
Journal:  Genomics       Date:  2011-11-03       Impact factor: 5.736

2.  A microdeletion at 12q24.31 can mimic beckwith-wiedemann syndrome neonatally.

Authors:  E Baple; R Palmer; R C M Hennekam
Journal:  Mol Syndromol       Date:  2010-01-11

3.  Outlier DNA methylation levels as an indicator of environmental exposure and risk of undesirable birth outcome.

Authors:  Jayashri Ghosh; Monica Mainigi; Christos Coutifaris; Carmen Sapienza
Journal:  Hum Mol Genet       Date:  2015-11-12       Impact factor: 6.150

4.  Wnt7b Signaling from the Ureteric Bud Epithelium Regulates Medullary Capillary Development.

Authors:  LaToya Ann Roker; Katrina Nemri; Jing Yu
Journal:  J Am Soc Nephrol       Date:  2016-07-18       Impact factor: 10.121

5.  Chromosome 11 segmental paternal isodisomy in amniocytes from two fetuses with omphalocoele: new highlights on phenotype-genotype correlations in Beckwith-Wiedemann syndrome.

Authors:  F R Grati; L Turolla; P D'Ajello; A Ruggeri; M Miozzo; G Bracalente; D Baldo; L Laurino; R Boldorini; E Frate; N Surico; L Larizza; F Maggi; G Simoni
Journal:  J Med Genet       Date:  2007-01-26       Impact factor: 6.318

Review 6.  Environmental epigenomics and disease susceptibility.

Authors:  Randy L Jirtle; Michael K Skinner
Journal:  Nat Rev Genet       Date:  2007-04       Impact factor: 53.242

Review 7.  The molecular genetics of adrenocortical carcinoma.

Authors:  Ferdous M Barlaskar; Gary D Hammer
Journal:  Rev Endocr Metab Disord       Date:  2007-12       Impact factor: 6.514

8.  Lessons from BWS twins: complex maternal and paternal hypomethylation and a common source of haematopoietic stem cells.

Authors:  Jet Bliek; Marielle Alders; Saskia M Maas; Roelof-Jan Oostra; Deborah M Mackay; Karin van der Lip; Johnatan L Callaway; Alice Brooks; Sandra van 't Padje; Andries Westerveld; Nico J Leschot; Marcel M A M Mannens
Journal:  Eur J Hum Genet       Date:  2009-06-10       Impact factor: 4.246

9.  Maternal Hypomethylation of KvDMR in a Monozygotic Male Twin Pair Discordant for Beckwith-Wiedemann Syndrome.

Authors:  S C Elalaoui; I Garin; A Sefiani; G Perez de Nanclares
Journal:  Mol Syndromol       Date:  2013-11-30

10.  Determination of KCNQ1OT1 and H19 methylation levels in BWS and SRS patients using methylation-sensitive high-resolution melting analysis.

Authors:  Marielle Alders; Jet Bliek; Karin vd Lip; Ruud vd Bogaard; Marcel Mannens
Journal:  Eur J Hum Genet       Date:  2008-10-15       Impact factor: 4.246

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.